Published in Oncology Business Week, May 16th, 2004
"The completion of enrollment in this trial, 10 months ahead of schedule, is a tribute to the diligence and commitment of InterMune and the investigators and underscores the urgent need for improved treatment regimens for this disease," said David S. Alberts, MD, regents professor of medicine, pharmacology, and public health, College of Medicine, University of Arizona, and lead principal investigator for the trial.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week